News|Articles|September 1, 2026

5 Psychiatry Headlines You Missed in 2026

Fact checked by: Tim Smith

A regulatory resubmission, 2 phase 3 psychedelic trial readouts, new TMS dosing data, and an MDD genetics study, all in this August 2026 recap.

August brought fresh movement in psychiatry's psychedelic pipeline, with a resubmission of the new drug application (NDA) for MDMA-assisted therapy and phase 3 data on lysergide for anxiety. TMS practice also saw new data this month, from a look back at how far session times have shrunk to fresh questions about whether current dosing conventions are even the right ones.